Announcements Trials
Browse Landscape

Status

Completed 129Terminated 32Recruiting 30Unknown 22Active not recruiting 22Withdrawn 12Not yet recruiting 8Enrolling by invitation 5No longer available 2Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 11Carcinoma, Non-Small-Cell Lung 11Neoplasms 8Prostatic Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Leukemia, Myeloid, Acute 4Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lambert-Eaton Myasthenic Syndrome 3HER2-positive Breast Cancer 3Glioma 3Carcinoma, Medullary 3Thyroid Neoplasms 2Stomach Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Myasthenic Syndromes, Congenital 2Lymphoma 2Liver Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Head and Neck Neoplasms 2

Interventions

pirtobrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × Hematologic Diseases × Clear all
NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Eli Lilly and Company

Approved for marketing
LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡